JP2018501829A - Medical and veterinary light irradiation for therapeutic compounds - Google Patents

Abstract

Medical and veterinary light irradiation of a therapeutic compound is a solution retainer suitable for holding a therapeutic solution to a user's tissue; a fiber optic cable; A light source provided to the optical fiber cable; and an optical termination of the optical fiber cable for irradiating the therapeutic solution with the light. The formulation comprises an oxidizing agent; a therapeutic solution having an initial therapeutic effect; and light of a predetermined wavelength that enhances the initial therapeutic effect of the solution by synergistic reaction with the oxidizing agent. [Selection] Figure 1

Description

RELATED APPLICATION This application claims the benefit of the filing date of US Patent Application No. 62 / 026,498 (P679-104) filed July 18, 2014, all of which are incorporated herein by reference. Claims the benefit of the filing date of US Patent Application No. 14 / 497,269 (P679-104A), filed September 24, 2014, all of which are hereby incorporated by reference; November 2014 Claims the benefit of the filing date of US patent application Ser. No. 14 / 536,633 (P679-104B) filed on the 9th, all of which are incorporated herein by reference; filed on Dec. 26, 2014 US patent application Ser. No. 14 / 583,580 (P679-104C), all of which are incorporated herein by reference and are incorporated herein by reference. Claims the benefit of the filing date of US patent application Ser. No. 14 / 630,513 (P679-104E) filed on the 4th, all incorporated herein by reference; filed on 4 March 2015 US Patent Application No. 14 / 638,902 (P679-104F), all of which are hereby incorporated by reference; US Patent Application No. filed April 27, 2015 No. 14 / 697,579 (P679-104D) claims the benefit of the filing date, all of which are hereby incorporated by reference.

  The present invention relates generally to treatments that include enhanced chemical effects by light, particularly to medical and veterinary light irradiation for antibacterial and anti-neoplastic chemicals, including antibacterial and anti-neoplastic solutions.

There are microorganisms that cause harm or disease in living tissues of humans and animals.
Tumors such as cancer or neoplasts can also cause harm to human and animal tissues.

  The light of a specific wavelength improves or “supercharges” the action of a specific chemical, or a target chemical such as an antibacterial substance, an anti-neoplastic agent (antineoplastic Agent) It was shown that. And it produced a synergistic effect that destroyed or inhibited the growth of microorganisms or neoplasms (malignant tumors).

  Specific anti-bacterial drugs or anti-neoplastic drugs (anti-neoplastic drugs) or both may be irradiated so that a synergistic effect is created to destroy or inhibit the growth of microorganisms or tumors desirable.

  In one aspect of the invention, the device is a solution retainer suitable for holding a therapeutic solution to a user's tissue; a fiber optic cable; coupled to the fiber optic cable, and a predetermined wavelength of light to the fiber optic cable. A light source provided; and an optical termination of the fiber optic cable for irradiating the therapeutic solution with the light.

  In another aspect of the invention, the formulation comprises a solution comprising an oxidant; a therapeutic solution having an initial therapeutic effect; and synergistically reacting with the oxidant to effect the initial therapeutic effect of the solution. Light of a predetermined wavelength to be strengthened.

FIG. 1 shows an embodiment of a dental wearing tool according to the present invention. FIG. 2 shows an embodiment of a container according to the present invention. FIG. 3 shows an embodiment of a bowl according to the present invention. FIG. 4 shows an embodiment of a full body suit according to the present invention. FIG. 5A shows an embodiment of a garment according to the present invention. FIG. 5B shows an embodiment of a garment according to the present invention. FIG. 5C shows an embodiment of a garment according to the present invention. FIG. 5D shows an embodiment of a garment according to the present invention. FIG. 5E shows an embodiment of a garment according to the present invention. FIG. 6 shows an embodiment of a helmet according to the present invention. FIG. 7 shows an embodiment of a catheter according to the present invention. FIG. 8 shows an embodiment of the blanket according to the present invention. FIG. 9A shows an embodiment of an animal cover according to the present invention. FIG. 9B shows an embodiment of the animal cover according to the present invention. FIG. 9C shows an embodiment of the animal cover according to the present invention.

  Preferred and other embodiments, including the best embodiments of industrial applicability and practice of the presently known invention, are described in detail herein with reference to the drawings. Further embodiments, features, and advantages will become apparent from the following description or may be learned without undue experimentation. Unless otherwise indicated, the drawings are not drawn to scale. The following description of embodiments is not to be construed as limiting, and the manner in which the invention is made and used, even if the phrase “present invention” or embodiment is “is” is used. And methods are described. The scope of this patent is set forth in the claims. The order of steps listed in the claims does not necessarily indicate that the steps must be performed. The word “and / or” between two element means means only the first element, only the second element, or both elements.

  Embodiments of the present invention generally provide devices and therapeutic solutions for medical and veterinary light irradiation of therapeutic compounds.

  Embodiments of the present invention generally provide a drug that has an effect that is enhanced by light irradiation of a predetermined wavelength on the drug.

  Embodiments of the present invention are in contact with tissue (eg, flesh, teeth, or animal flesh) such that the tissue and solution are simultaneously irradiated with light of a specific wavelength. An apparatus for holding the solution may be provided. The device may include components that use a specific wavelength of light to increase the effectiveness of the antimicrobial solution. Antimicrobial substances, anti-neoplastic agents, or other therapeutic solutions may or may not be photoactivated at a given time. When the light is on, the therapeutic solution is “supercharged” by the light. This synergistic effect eliminates or reduces more microorganisms than would work with the solution alone.

  An embodiment of the therapeutic solution may be an oxidant, antibacterial or anti-tumor so as to be tissue (eg, human or animal flesh) so that the tissue and solution are simultaneously irradiated with light of a specific wavelength. Neoplastic drugs may be retained. Embodiments may include components that use specific wavelengths of light to increase the effectiveness of antibacterial, antiviral, anti-neoplastic solutions. When light is irradiated onto the solution, the solution is “supercharged” by the light. This synergistic effect eliminates or reduces more microorganisms or tumors than would work with the solution alone. This may be due to various means including light from a direct light source, or from a light source coupled to a dental tray or other tray or container (mask, bandage, horse blanket or animal cover) or treatment In order to achieve this, an apparatus that provides antibacterial or anti-neoplastic chemicals may be used.

  There are microorganisms that cause harm or disease in living tissues. By irradiating a device of a specific wavelength adjacent to the tissue and holding a specific therapeutic agent, a synergistic effect can be created that destroys or inhibits the growth of microorganisms or neoplasms. For example, in the oral cavity, the appliance can be a tray designed to cover teeth or gums. This tray emits light of a specific wavelength, which causes a synergistic antibacterial and / or anti-neoplastic effect when combined with specific antibacterial and / or anti-neoplastic solutions in the tray. The light may be generated from, for example, a light emitting diode (LED) or a laser. An external light source may be coupled to the fiber optic cable in a solution holding device that includes a fiber optic coupling cable and may further comprise a fiber optic coupling interface or plug.

  Embodiments of the present invention may generate another means of treating a disease. Supercharging an antibacterial or antineoplastic solution with light of a specific wavelength (supercharging) can cause the solution to remove or reduce microorganisms and tumor tissue at a higher percentage than with that solution alone. . Embodiments can generate a synergistic effect between light of a specific wavelength and an antibacterial and / or anti-neoplastic solution, causing microorganisms and / or neoplastic tissue when the solution is provided to the tissue. To eliminate or reduce the disease

  Embodiments of the present invention may comprise a solution holding device or a medium that emits light of a specific wavelength to the solution. When the combination of light and solution is provided to the tissue, a synergistic effect is created that reduces or eliminates disease-causing microorganisms and / or tumor tissue. There is one essential component. Solution holding device 2. Light source 3; Antibacterial solution or antineoplastic solution or both.

Embodiments may use blue light with exposures from seconds to minutes, or may use some other predetermined wavelength of light that supercharges the solution. Embodiments may include a H ₂ 0 ₂ solution at a concentration of 0.3 mM, or any suitable solution such as antibacterial, antiviral, anti-neoplastic drugs or compounds, eg in gel form.

In embodiments, for safety, a “scalding chart” is safe to be exposed to 130 degrees Fahrenheit in less than 30 seconds, but more may indicate that it will cause burns. Good. Hot water at 120 degrees Fahrenheit may be safe for up to 5 minutes. If hydrogen peroxide _{(H 2 0} 2) is irradiated by light having a wavelength of 400-500 nm, the hydrogen peroxide _{(H 2 0} 2) can kill 96% of the microorganisms in less than 20 seconds . This solution is most effective at 57 degrees Celsius (134 degrees F).

  An alternative embodiment may include a heating element that warms and super-charges the therapeutic solution. In embodiments, the device may include heating or cooling elements or both. In embodiments, the antibacterial solution may be preheated to an ideal or optimal temperature before the antibacterial solution is irradiated by synergistic light or used at a changing or unchanging pH. For example, hydrogen peroxide may be irradiated with 400-500 nanometer light, preferably at 57 degrees Celsius (134 degrees F) for less than 20 seconds. Other chemicals may have different preferred temperatures and pHs.

  Embodiments of a medical or veterinary device may include an integrated or internal heating element that extends adjacent to a light emitting cable in the device. Integrated heating element embodiments may be located on only a portion of the device, such as a container, garment, or cover bottom. The heating element may obtain power from the same power source as the light source, such as a battery or wall outlet. In the device, power may be supplied to the heating element by an optical fiber connection cable or by a power connection cable extending along the connection cable.

  Alternative embodiments of the heating element may be separate from the portion of the device that holds the therapeutic solution. A separate heating element may warm the therapeutic solution at the optimum temperature, for example by a heating tray or oven, before the solution is added to the device, or it may be in place, for example by a hot iron or wire. May be used to heat the antibacterial or anti-neoplastic solution.

  Embodiments of the device may include a light emitting fiber optic cable capable of irradiating the therapeutic solution with light of a specific wavelength, such as a wavelength selected for purpose or a wavelength of light from an LED or laser. The cover may hold an antimicrobial solution. Embodiments may include multiple light terminations or other light emitters on the light emitting fiber optic cable. Each light termination enters the fiber optic cable and emits light out of the end of the termination, thereby emitting light to the therapeutic solution. The device may be adjustable so that the termination can be added and moved, or the amount and position of the optical termination can be measured to fit an individual user. The light terminations may also be located inside or on the surface of the cover so that each light termination is located at a preselected location within the retainer, for example, in the vicinity of the treated tissue. Good. The fiber optic cable may be dull with a light emitter spaced along its length, and may be at least partially translucent to emit light along its length. The user may be a human or an animal.

  In an embodiment, the optical fiber cable may be connected to the light source by an optical fiber connection cable. The coupling cable may enter the retainer or cover so that the light source can be coupled and removed after use, and may be optically coupled to the fiber optic cable by a fiber optic coupling interface. Interface embodiments may include a fiber optic connecting cable attached to the fiber optic cable. Other embodiments of the interface may include a socket that mates with the plug on the connecting cable so that the light source can be coupled and removed after use.

  Embodiments may include a device comprising a light source and an antimicrobial and / or antimicrobial solution. Embodiments may include various human or animal body or body covers.

  Embodiments of the invention may include a retainer or cover that provides a therapeutic solution to a human, horse, or other animal. The retainer may be connected to the light source. Embodiments may include multiple fiber optic terminations. The cage may comprise a heating element.

  Embodiments of the cage include a dental tray that holds antibacterial, anti-neoplastic, or other therapeutic solutions for the user's teeth; holds antibacterial, anti-neoplastic solutions for human user tissue Medical solution retainer suitable for: Bucket or container; Bowl; Full body suit; Arm sleeve; Gloves; Leg stocking; Toe cap; Helmet; Catheter tube; Antibacterial and anti-neoplastic solution against animal tissue A medical or therapeutic solution retainer suitable for holding; a blanket for horses or other animals; or a cover for limbs or parts of animals.

  Embodiments may include fiber optic cables that wrap around the internal surface of the device. The fiber optic cable may have optical terminations spaced along the fiber optic cable in the device. Embodiments may include a heating element within the device. The heating element may include a heating wire that extends adjacent to the fiber optic cable in the apparatus. The optical fiber cable may be connected to the light source by a connection cable. The connection interface or plug may or may not connect the external light source to the device. The heating elements may receive power from the light source by the same light source connection cable or by separate power connection cables. The switch may be connected to the light source, heating power, or both, or may be switched on or off.

  To practice the embodiments, the therapist may provide a therapeutic solution to the interior of the device to give the device to a person or animal undergoing treatment. The therapist may turn on the heater or light source or both.

  Embodiments of the therapeutic solution may include antibacterial, antiviral, anti-neoplastic compounds that come into contact with human or animal skin. This solution may be in the form of a liquid, gel, mist, cream or other suitable form. The solution may or may not be heated by the device. Embodiments may or may not include a compound that adjusts the pH of the solution.

Embodiments may include a light source that emits light of a specific wavelength, such as 400-500 nM. The light source may be hand help. The light source may be in contact with the therapeutic solution, or may be held or placed within a distance of effect. The combination of antibacterial and / or anti-neoplastic solutions and specific wavelengths of light can produce a synergistic effect that causes a reaction (synergistic effect) that is greater than the sum of the individual component reactions.
In order to treat acne, actinic keratosis, or any other skin or systemic symptom or disease, embodiments of such combinations of light with specific wavelengths and antibacterial and / or anti-neoplastic solutions are utilized. May be.

  When provided, the antibacterial, antiviral, anti-neoplastic or other therapeutic chemical may be irradiated by the wavelength of light that produces a synergistic effect that enhances the effect of the therapeutic chemical. This synergistic effect results in a significant reduction of bacteria associated with cancer or tumors rather than the use of therapeutic solutions alone or light alone.

  In an embodiment, the chemical may be used without a storage container. The chemical substance may be inserted directly into the body cavity, or may be irradiated with light by an optical fiber wand having a plurality of light emitting fibers. Embodiments of the carrier or reservoir can be the solution itself or a gel. This gel may be inserted into the body cavity with a catheter and may be irradiated with synergistic light with the same or different catheters. Delivery devices include storage containers, bandages, gels, solutions, head covers, animal covers, wraps, socks, stockings, hats, helmets, mists, suits, tents, probes or catheters. It is not limited to.

Hydrogen peroxide (H ₂ O ₂ ) can be an oxidizing or reducing agent. When H ₂ 0 ₂ is used as the oxidant, oxygen is reduced to H ₂ 0. When H ₂ 0 ₂ is used as the reducing agent, oxygen participates and becomes 0 ₂ and bubbles are observed. As an oxidizing or reducing agent that provides antibacterial, anti-neoplastic and / or antiviral effects, embodiments of the present invention may utilize H ₂ 0 ₂ and H ₂ 0 ₂ formulations. Formulation or drug, if it contains H ₂ 0 _2, including the "oxidizing agent".

Drug embodiments consisting of multiple components, including light of a wavelength, and multiple chemicals, either alone or in combination, inhibit, retard, and / or the growth of microorganisms and / or viruses and / or neoplasms Or stop it. A drug may resemble antibacterial and / or antiviral and / or anti-neoplastic chemicals with respect to their chemical and functional profiles in vivo. The medicine may have light as one of its components. It reliably produces antibacterial and / or antiviral and / or anti-neoplastic effects in humans and other animals, with clinically defined doses. It is specified for specific wavelengths of light, including at least one or more of the following chemicals; H ₂ 0 ₂ , lauric acid, dodecanoic acid, topical antibiotics Topical anesthetics, nicotinic acid, nicotinamide, antimicrobials such as clindamycin phosphate, methyl 7-chloro-6,7,8 3-deoxy-6- (1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamide) -1-thio-L-threo-α-D-galacto-octopyranoside 2- (dihydrogen phosphate) ( Methyl 7-chloro-6,7,8-trideoxy-6- (l-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido) -l-thio-L-threo-α-D-galacto-octopyranoside 2- (dihydrogen phosphate)), salicylic acid, sulfur Such as 6- [3- (1-adamantyl) -4-methoxyphenyl] naphthalene-2-carboxylic acid (6- [3- (l-adamantyl) -4-methoxy-phenyl] naphthalene-2-carboxylic acid) Retinoid, alpha hydroxy acid, tretinoin, borax, caprylic acid, capric acid, myristic acid, and the above method Additive chemicals useful for

The dosage form of the present invention may consist of a compound of light of a certain wavelength and one or more of the following chemical substances: H ₂ 0 ₂ , lauric acid, dodecanoic acid, topical antibiotics Substances (topical antibiotics), topical anesthetics, nicotinic acid, nicotinamide, antimicrobials such as clindamycin phosphate, methyl 7-chloro- 6,7,8-Trideoxy-6- (1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamide) -1-thio-L-threo-α-D-galacto-octopyranoside 2- (dihydrogen Phosphate) (Methyl 7-chloro-6,7,8-trideoxy-6- (l-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido) -l-thio-L-threo-α-D- galacto-octopyranoside 2- (dihydrogen phosphate)), salicylic acid, sulfur sulfur), 6- [3- (1-adamantyl) -4-methoxyphenyl] naphthalene-2-carboxylic acid (6- [3- (l-adamantyl) -4-methoxy-phenyl] naphthalene-2-carboxylic acid) Such as retinoid, alpha hydroxy acid, tretinoin, borax, caprylic acid, capric acid, myristic acid, and An additive chemical useful in the above method, comprising a pharmacologically acceptable carrier.

  Target chemical embodiments may include one or more of antibacterial, bactericidal, or antiseptic compounds. Antimicrobial embodiments may include chlorhexidine compounds. Embodiments of the target chemical may include non-steroidal anti-inflammatory compounds such as, for example, indene derivatives. Embodiments of the target chemical may include an iodine compound. Embodiments of target chemicals may include members of the TNF family of tumor necrosis factor or cytokines. Target chemical embodiments may include silver (Ag) or metals such as transition metals such as Cu or Fe. The target chemical embodiment may comprise an enzyme. Enzyme embodiments may include one or more of proteases, pectinases, or elastases. Target chemical embodiments may include antineoplastic agents. Embodiments of the target chemical may include antibiotics such as ciprofloxacin. Embodiments of the target chemical may include antispasmodic drugs such as methylene bicloride.

  In embodiments, the first reaction may include light of a particular wavelength, such as 400-500 nanometers, combined with an oxidant such as hydrogen peroxide. The light plus oxidant may be therapeutic alone. The second reaction may include a specific wavelength of light combined with the target chemical that is combined with the oxidant and undergoing a synergistic reaction. Drug embodiments may include a light-enhanced oxidant and a light-enhanced target chemical to provide a drug with a light-enhanced therapeutic effect. The drug may be a solution that is held in contact with the user while illuminated by light from the light source, or the solution may be enhanced by light prior to delivery. The light may include two wavelengths that are applied simultaneously to the drug or solution, or in series, irradiated with light of the first wavelength, and then light of the second wavelength. May be irradiated.

  The selected target chemical may be used in combination with a surfactant, a wetting agent, a chelating agent, or a useful additive. Medical drug embodiments may be used in the form of tablets, tablets, capsules, gels, liquids, sprays, mists, creams, or pastes. Embodiments may be used at various temperatures to adjust their effectiveness.

  Dentistry. FIG. 1 shows an embodiment of a dental device 10. The light emitting fiber optic cable 12 may be irradiated with the antimicrobial solution 14 by light of a specific wavelength, such as a wavelength selected for purpose or a wavelength of light from an LED or laser. The tray 16 may hold the antibacterial solution 14. Embodiments may include multiple light terminations 18 or other light emitters on the light emitting fiber optic cable 12. Each light termination 18 enters the optical fiber cable 12 and emits light outward from the end 18, thereby emitting light to the antimicrobial solution 14. The device may be adjustable so that the end 18 can be added and moved, or the amount and position of the light end 18 can be measured to fit an individual user. The light terminations 18 may be located inside the tray 16 such that each light termination 18 is positioned between or adjacent to the user's adjacent teeth. The fiber optic cable may be dull with a light emitter spaced along its length, and may be at least partially translucent to emit light along its length. In the embodiment, the optical fiber cable 12 may be connected to the light source 20 by the optical fiber connection cable 22. The connection cable 22 may enter the tray 16 and may be optically connected to the fiber optic cable 12 by the fiber optic connection interface 24 so that the light source 20 can be coupled and removed after use. Embodiments of the interface 24 may include an opening in the tray 16 wall that attaches the fiber optic connecting cable 22 to the fiber optic cable 12. Other embodiments of the interface 24 may include a socket on the tray 16 that mates with a plug on the connecting cable 22 so that the light source can be coupled and removed after use.

  container. As shown in FIG. 2, an embodiment of the medical device 30 may include a container 32 that includes a wall 34, a bottom 36, and a carry handle 38. Embodiments may include fiber optic cable 40 that wraps up the inner surface of wall 34. The optical termination 42 may be disposed on the fiber optic cable 40 in the container. The heating element 44 may be located around the bottom of the container 32. The optical fiber cable 40 may be connected to the light source 46 by an optical fiber connection cable 48.

  bowl. As shown in FIG. 3, an embodiment of the medical device 50 may include a bowl 52 having a fiber optic cable 54 that wraps around an interior surface 56 of the bowl 52. The fiber optic cable 54 may have an optical termination 58. Embodiments may have a base 60 and may include a heating element 62. The optical fiber cable 54 may be connected to the light source 64 by an optical fiber connection cable 66. The light source 64 may include an on / off switch 68 or a timer control 69.

  Full body suit. As shown in FIG. 4, an embodiment of the medical device 70 includes an integrated torso 74, sleeve 76, pants 78, feet 80, and hood 82, and removable gloves 84 or mittens 86. A full body suit 72 having The sleeve 76 may include a cuff 88 to fit against the user's wrist. The hood 82 may have an elastic part 90 in order to tighten against the user's face. Embodiments may include, for example, an injection tube 92 on one shoulder of the barrel 74 and may include an exhaust tube 94 on the other shoulder of the barrel 74. Embodiments may include a fiber optic cable 96 spaced along the tissue within the suit 72. The optical termination 98 may be disposed on the fiber optic cable 96 within the suit 72. The heating element may be embedded in the fabric of the suit 72. The fiber optic cable 96 or the heating element or both may be coupled to the light source by a fiber optic coupling cable.

  clothes. FIGS. 5A, 5B, 5C, 5D and 5E show an embodiment of a medical device comprising a garment that carries a light enhanced antimicrobial solution to a user wearing the garment. FIG. 5A shows an embodiment of arm sleeve 122. FIG. 5B shows an embodiment of a glove 124. FIG. 5C shows an embodiment of the toe cap 126. FIG. 5D shows an embodiment of a thigh sock with a toe cover 128 or a toeless cover 130. FIG. 5E shows an embodiment of a 1 foot sock 132 with a waistband 134.

  helmet. As shown in FIG. 6, an embodiment of the medical device 140 may include a helmet 142 having a fiber optic cable 144 that wraps around the interior surface 146 of the helmet 142. The fiber optic cable 144 may have an optical termination 148. Embodiments may include a heating element 150 that includes a wire on the back of the helmet. The optical fiber cable 144 may be connected to the light source 152 by an optical fiber connection cable 154.

  catheter. As shown in FIG. 7, an embodiment of the medical device 160 may include a catheter tube 164 with one or more light terminations 170, a mesh dispenser screen 166, and a catheter 162 with a fiber optic cable 168. . The heating element 172 may be external to the catheter tube 164 and may provide the antimicrobial solution 174 warmed by the infusion tube 176. The light source 178 may be connected to the optical fiber cable 168 by the optical fiber connection cable 180 together with the optical fiber connection interface 182.

  Horse blanket. As shown in FIG. 8, an embodiment of a full blanket 200 for horses may include a cover portion 202, a neck portion 204, and an upper foot portion 206. Blanket 200 may include a string 208 to hold the cover closed. The inside of the blanket 200 may be coated with an antibacterial solution or gel. The embodiment may include an optical fiber cable 210 that winds the inner surface with the cover portion 202. Embodiments may include a heating element 212 and may include a heating wire in the cover portion 202. Embodiments may include a coupling interface 214 that couples the fiber optic cable 210 to the light source 216. The optical termination 218 may be disposed on the fiber optic cable 210 within the blanket 200. The light source 216 may have an on / off switch 220 or a timer control.

  Animal cover. As shown in the embodiment of FIGS. 9A, 9B and 9C, the animal cover 230 may include a soft plastic sheet 232 and an attachment mechanism 234 at one end of the sheet 232. The cover 230 wraps around the animal's neck, and the attachment mechanism 234 on one end of the seat 232 may be attached to the opposite side of the seat 232 to form a loop. Embodiments may include a soft cloth trim 236 on the top and bottom sides where the cover 230 is covered by an animal or other object. The cover 230 may be coated with an antimicrobial solution or gel on the inside. The embodiment may include a fiber optic cable 238 that winds the inner surface of the sheet 232. Embodiments may include a heating element 240 comprising a wire within the heating cover. Embodiments may include a connection interface 228 that connects the fiber optic cable 238 to the light source 242. The optical termination 244 may be disposed on the fiber optic cable 238 within the blanket. The light source 242 may have an on / off switch 246 or timer control.

  Embodiments of a method for treating acne vulgaris (“acne”) include topical antibiotics, topical anesthetics, nicotinic acid, nicotinamide (Nicotinamide), antimicrobial substances such as clindamycin phosphate, methyl 7-chloro-6, 7, 8-trideoxy-6- (1-methyl-trans-4-propyl-L -2-pyrrolidinecarboxamide) -1-thio-L-threo-α-D-galacto-octopyranoside 2- (dihydrogen phosphate) (Methyl 7-chloro-6,7,8-trideoxy-6- (l- one or more other antibacterial substances or others consisting of methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido) -l-thio-L-threo-α-D-galacto-octopyranoside 2- (dihydrogen phosphate)) Peroxidation with light in a specific wavelength range, used in combination with other chemicals Iodine solution may be provided in a therapeutically effective amount of. Embodiments of antibacterial substances include salicylic acid, sulfur, 6- [3- (1-adamantyl) -4-methoxyphenyl] naphthalene-2-carboxylic acid (6- [3- (l-adamantyl ) -4-methoxy-phenyl] naphthalene-2-carboxylic acid), retinoid, glycolic acid, tretinoin, borax, and additive chemicals useful in the above method May be included. Embodiments of local and global therapeutic agents include hydrogen peroxide, carbamide peroxide, sulfur, 6- [3- (1-adamantyl) -4-methoxyphenyl] Retinoids such as naphthalene-2-carboxylic acid (6- [3- (l-adamantyl) -4-methoxy-phenyl] naphthalene-2-carboxylic acid), glycolic acid, borax ), Resorcinol, salicylic acid, benzoyl peroxide, vitamin A acid (tretinoin), and topical and systemic antibiotics, It may be utilized as a therapeutic chemical in an embodiment of the invention for treatment. Embodiments comprising a combination of various peroxide compounds with certain chemicals are effective in treating acne and have a greater synergistic effect in acne treatment than would be expected by treatment with the individual drugs themselves. When illuminated by light of a specific wavelength, the synergy has an even greater synergy. Because the second chemical is effective in reducing acne and contains elements used in acne treatment or acne related therapies, the second chemical becomes a therapeutic or acne treatment chemical. obtain.

  For example, studies have shown that embodiments using hydrogen peroxide kill 30% of bacteria exposed to hydrogen peroxide for 20 seconds. Light with a wavelength of 360 nM-500 nM can kill 3% of bacteria irradiated with the light for 20 seconds. Hydrogen peroxide combined with 360 nM-500 nM light can show a synergistic reaction that kills 96% of bacteria exposed to the combination for 20 seconds. The composition of the solution used in the embodiment of the present invention is hydrogen peroxide and / or carbamide peroxide and / or benzoyl peroxide, sulfur, 6- Retinoids such as [3- (1-adamantyl) -4-methoxyphenyl] naphthalene-2-carboxylic acid (6- [3- (l-adamantyl) -4-methoxy-phenyl] naphthalene-2-carboxylic acid) retinoid, glycolic acid, borax, resorcinol, salicylic acid, vitamin A acid (tretinoin), and topical and systemic antibiotics One or more combinations of substances may be included.

  In embodiments of the present invention, topical solutions of hydrogen peroxide and / or carbamide peroxide and / or benzoyl peroxide and other chemicals that are considered effective may be delivered in various organic solvents or carriers. May be. Carrier embodiments may include a combination of ethyl alcohol and propylene glycol, where the active ingredient may be present in a range from about 0.001% to about 50% by volume of the carrier. The pH of the solution may be adjusted so that it does not interfere with the effect of the solution and tissue sensitivity is minimized. The temperature of the solution may be adjusted to optimize its effect.

  For safety and to optimize the effectiveness of the solution, a “scalding chart” may be provided and used. The chart is safe to be exposed to 130 degrees hot water in less than 30 seconds, but more may indicate that it causes burns. 120 degrees hot water may be safe for up to 5 minutes. Solutions warmer than normal body temperature tend to open pores that expose bacteria to larger amounts of lysis. Systemic antimicrobial agents may be used as part of the treatment embodiment to increase its effectiveness. The solution may be irradiated with light of an effective 360 nM-600 nM wavelength or any other wavelength for a predetermined time from 1 second to 1 minute. Embodiments may include a warmed solution and the light produces a synergistic effect that is unique to the present invention. The light may be used at various distances from the solution to adjust its synergistic effect.

  In a further embodiment, the topical solution of peroxide compound comprises hydrogen peroxide and / or carbamide peroxide and / or benzoyl peroxide at concentrations varying from 0.001 to 50% by volume of the various organic carriers. May be included. In embodiments, the compound may be incorporated into various vehicles or carriers, including solutions, lotions, creams, gels, mists, pastes, and ointments, with one or more of the following ingredients. : Nicotinic acid or nicotinamide present at a concentration of 0.001% to 30% by volume of the carrier; erythromycin present at a concentration of 0.001% to about 30% by volume of the carrier Erythromycin base; clindamycin phosphate; methyl 7-chloro-6,7,8-trideoxy-6- (1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamide) ) -1-thio-L-threo-α-D-galacto-octopyranoside 2- (dihydrogen phosphate) (Methyl 7-chloro-6,7,8-trideox) y-6- (l-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido) -l-thio-L-threo-α-D-galacto-octopyranoside 2- (dihydrogen phosphate)). Embodiments include a concentration of 0.001% to 30% by volume; tetracycline hydrochloride at a concentration of 0.001% to 30% by volume of the carrier; 6- [3- (1-adamantyl)- Retinoids such as 4-methoxyphenyl] naphthalene-2-carboxylic acid; and effective in treating acne It may have other components that are considered to be of interest. In embodiments, such carriers serve to incorporate carbamide peroxide and are a combination of ethyl alcohol and propylene glycol, lauryl ethers and lauryl esters. ) And other carriers effective in the present invention may be included. The carrier and effective ingredients may be used on the face of acne patients or other infected areas. This treatment may be provided at various intervals, such as 1 to 4 times during a 24-hour period, thereby opening and closing the comedone (blackhead and whitehead). Within a period of days to weeks, depending on the number of times the treatment is performed, the inflamed lesions are greatly reduced.

  Embodiments of the present invention include effective amounts of peroxide therapeutics alone, or topical antibiotics, local anesthetics, nicotinic acid, nicotinamide, antimicrobials, salicylic acid, sulfur, retinoids (eg, 6- [3 -(1-adamantyl) -4-methoxyphenyl] naphthalene-2-carboxylic acid (6- [3- (l-adamantyl) -4-methoxy-phenyl] naphthalene-2-carboxylic acid)), glycolic acid, tretinoin, An improved method can be provided for the treatment of acne that periodically provides an antibacterial solution comprising borax and a peroxide therapeutic combined with one or more of the additional chemicals useful in the method. . This antibacterial solution may be provided to patients with inflammatory diseases (acne). The antimicrobial solution may be adjusted to a temperature that is optimal for this treatment. An antibacterial solution may be provided over inflamed tissue associated with acne disorders. When provided, the antimicrobial solution may be irradiated by light of a wavelength that produces a synergistic effect that enhances the effect of the antimicrobial solution. This synergistic effect can cause a reduction in bacteria associated with acne that is greater than the use of antimicrobial solution alone or light alone.

  Embodiments of the solution may include a light activated pigment that can emit fluorescence when irradiated with light of the wavelength used in the procedure. The pigment can inform the user that a synergistic effect has occurred.

  The following specific examples illustrate the invention but do not limit the invention.

Example 1
In one embodiment, a solution of 3% hydrogen peroxide in a gel carrier is provided. Twice a day, topical delivery of the solution is made to the infected area of a patient suffering from acne vulgaris. After application, the solution is irradiated with light at a wavelength of 360 nM-500 nM for 20 seconds, producing a greater synergistic effect than providing light alone or solution alone. This light is provided by an LED device that irradiates all infected areas of the patient at once. The solution is then rinsed with clean water. After 2 weeks of the treatment, the total number of comedones on the patient and the inflamed areas resulting from acne infections were clearly reduced. This synergistic effect between solution and light is unique to the present invention.

Example 2
In another embodiment, a solution containing 3% hydrogen peroxide, 3% benzoyl peroxide, and salicylic acid is combined in a creamy carrier. The solution is kept at pH 6. The cream is applied to the patient's acne-infected area once a day. When the cream is applied, the cream is illuminated by 10 watts of light with a hand help light emitting wavelength of 410 nM-500 nM, so that the light or the solution acts alone. It provides a synergistic effect between the solution and the light that causes a large microbial reduction. The light may have a terminal that emits the light with a diameter of 15 mm. This particular size allows the patient to target a small area. The irradiation time of light is 1 minute. This embodiment of the invention may be used to maintain areas that have previously shown an acne infection in progress. This synergistic effect between solution and light is unique to the present invention.

Example 3
In yet another example, 15% carbamide peroxide, 2.5% clindamycin phosphate, methyl 7-chloro-6,7,8-trideoxy-6- (1-methyl-trans-4-propyl) -L-2-pyrrolidinecarboxamide) -1-thio-L-threo-α-D-galacto-octopyranoside 2- (dihydrogen phosphate). Examples may include tretinoin and are combined in a gel carrier. The carrier solution is heated to 105 degrees Fahrenheit. When provided to the infected area, the warmed solution helps to pierce the patient. The solution is provided 3 times per day. The infected area is illuminated by light with a wavelength of 410 nM-500 nM from a lamp that illuminates a 30 centimeter diameter area. Infected areas and solutions are illuminated with light of that particular wavelength for 30 seconds. The synergistic effect of light and warmed solution is greater than the effect of light or solution acting alone. This synergistic effect between the light and the warmed solution is unique to the present invention.

Claims (15)

A solution retainer, suitable for holding a therapeutic solution for the user's tissue,
Fiber optic cable,
A light source coupled to the fiber optic cable and providing light of a predetermined wavelength to the fiber optic cable; and a light termination on the fiber optic cable for irradiating the treatment solution with the light;
A device comprising: The solution has an initial microbial effectiveness;
The device of claim 1, wherein the light synergizes with the therapeutic solution to enhance the antimicrobial effect of the therapeutic solution. The solution has an initial microbial effectiveness;
The device of claim 1, wherein the light synergizes with the therapeutic solution to enhance the antimicrobial effect of the solution. The therapeutic solution is hydrogen peroxide;
The device of claim 1, wherein the light provides a synergistic response that enhances the antimicrobial effect of the therapeutic solution. The therapeutic solution is an oxidant combined with a carrier;
The device of claim 1, wherein the light provides a synergistic response that enhances the acne treatment effect of the therapeutic solution. The therapeutic solution is an antineoplastic agent;
The device of claim 1, wherein the light provides a synergistic response that enhances the anti-cancer effect of the therapeutic solution.   The apparatus of claim 1, further comprising a heating element that wraps around the interior of the solution retainer to warm the therapeutic solution during application. An external light source providing the light of a predetermined wavelength;
The optical fiber connection cable for optically connecting the light source to the optical fiber cable; and the socket of the solution retainer that engages with a plug on the optical fiber connection cable so that the light source is removable. apparatus. The solution retainer comprises the dental tray for holding a therapeutic solution in a cavity on the side of the dental tray;
The fiber optic cable is held in the tray;
The tissue is the user's teeth;
The tray is shaped to hold the irradiated therapeutic solution against the teeth;
The apparatus further includes a plurality of light terminations on the fiber optic cable that emit light from the fiber optic cable to the therapeutic solution, such that at least one light termination is adjacent to each of the two sides of each tooth. The apparatus of claim 1, wherein the optical termination is disposed and is a sufficient amount.   The apparatus of claim 1, wherein the fiber optic cable comprises an outer shield that covers only a portion of the light emitting core and the light emitting core so that the light is directed toward the fiber optic cable. The solution retainer is
Full body suit for humans;
An injection tube for injecting the therapeutic solution as a mist;
The area in the suit where the mist is circulated to the user;
A discharge tube for discharging the mist from the suit;
The apparatus of claim 1, wherein the fiber optic cable wraps the inner surface of the full body suit. The solution retainer is
An arm sleeve that covers the arm of a human user and provides the therapeutic solution;
A glove that covers a human user's hand or part of the hand and provides the therapeutic solution;
A leg stocking covering the leg or part of the leg of a human user to provide the therapeutic solution;
A toe cap covering one or more toes of a human user to provide the therapeutic solution;
A helmet that covers the human user's head and provides the therapeutic solution; and is shaped to cover the back, back, shoulders, sides, and back of the animal and closes around the animal The apparatus of claim 1, comprising a garment selected from the group consisting of: a blanket further comprising a strap with a securing element for removably securing the blanket to be removed. The solution retainer is
A catheter tube that receives the therapeutic solution at a first end of the catheter tube; and a catheter tube opposite the first end for dispensing the therapeutic solution to the user. A mesh in the catheter tube near the second end;
The apparatus of claim 1, wherein the optical termination is disposed on a fiber optic cable near the mesh. A solution containing an oxidizing agent;
A formulation comprising: a therapeutic solution having an initial therapeutic effect; and light of a predetermined wavelength that enhances the initial therapeutic effect of the solution by synergistic reaction with an oxidizing agent. The therapeutic solution includes a target chemical coupled with an oxidant, and the binding solution synergizes with light to enhance the antibacterial, antiviral, anti-neoplastic effects of the therapeutic solution;
The target chemical substance is
Antibacterial, bactericidal or disinfecting compounds;
Antimicrobial compounds including chlorhexidine;
Non-steroidal anti-inflammatory compounds including indene derivatives;
Iodine compounds;
Tumor Necrosis Factor;
A protease, pectinase or elastase compound;
Ciprofloxacin;
15. A formulation according to claim 14 selected from the group consisting of an antispasmodic; and methylene bicloride.